LEADER 03697nam 22007335 450 001 9910766881303321 005 20250211123728.0 010 $a9789819966981 010 $a9819966981 024 7 $a10.1007/978-981-99-6698-1 035 $a(MiAaPQ)EBC30974059 035 $a(Au-PeEL)EBL30974059 035 $a(DE-He213)978-981-99-6698-1 035 $a(CKB)29089599500041 035 $a(EXLCZ)9929089599500041 100 $a20231126d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEngineered Biomaterials $eSynthesis and Applications /$fedited by Rishabha Malviya, Sonali Sundram 205 $a1st ed. 2023. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2023. 215 $a1 online resource (623 pages) 225 1 $aEngineering Materials,$x1868-1212 311 08$aPrint version: Malviya, Rishabha Engineered Biomaterials Singapore : Springer,c2024 327 $a1. Naturally Derived Biomaterials: Advances and Opportunities -- 2. Different Techniques of Genetic Engineering Used for the Development of Novel Biomaterials -- 3. Green methods for the development of bone and tissue engineering based biomaterials -- 4. Genetically Induced Biomaterial Advances in Medical Science -- 5. Biomimetic approach for biomaterials development. 330 $aThis book highlights recent advances focusing on the synthesis methods of engineered biomaterials and their applications. The book discusses recent applications of various approaches and technology in improving the functional properties and biological activities of biopolymers. It includes two major sections: the first section introduces a range of methods which lead to materials with enhanced properties for a range of practical applications, along with the positives and limitations of the techniques. The second section covers recent trends and advances in application of engineered biomaterials that assist materials scientists and researchers in mapping out the future of these new improved materials through value addition in order to enhance their use. Contributions in the book are done by prominent researchers from industry, academia, and government/private research laboratories across the globe. The book summarizes in a fairly comprehensive manner many of the recent technical advancements in the area of biopolymers. The book is intended to serve as a reference resource in the area of polymers science. 410 0$aEngineering Materials,$x1868-1212 606 $aMedical physics 606 $aBiomaterials 606 $aBiomedical engineering 606 $aNanobiotechnology 606 $aCancer$xTreatment 606 $aNanoscience 606 $aMedical Physics 606 $aBiomaterials 606 $aBiomedical Engineering and Bioengineering 606 $aNanobiotechnology 606 $aCancer Therapy 606 $aNanophysics 615 0$aMedical physics. 615 0$aBiomaterials. 615 0$aBiomedical engineering. 615 0$aNanobiotechnology. 615 0$aCancer$xTreatment. 615 0$aNanoscience. 615 14$aMedical Physics. 615 24$aBiomaterials. 615 24$aBiomedical Engineering and Bioengineering. 615 24$aNanobiotechnology. 615 24$aCancer Therapy. 615 24$aNanophysics. 676 $a610.153 700 $aMalviya$b Rishabha$01430067 701 $aSundram$b Sonali$01430068 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910766881303321 996 $aEngineered Biomaterials$93650084 997 $aUNINA LEADER 05496nam 2201465z- 450 001 9910557432803321 005 20210501 035 $a(CKB)5400000000043395 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68346 035 $a(oapen)doab68346 035 $a(EXLCZ)995400000000043395 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMetabolic Syndrome$eFrom Etiology to Prevention and Clinical Management 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (348 p.) 311 08$a3-03943-989-8 311 08$a3-03943-990-1 330 $aMetabolic syndrome has been the topic of countless publications. It still remains a subject of debate and some experts have even questioned its clinical relevance. Its diagnosis is nevertheless predictive of an increased risk of type 2 diabetes and cardiovascular disease even in the absence of traditional risk factors. Many years ago, our team made the point that the most prevalent form of metabolic syndrome was linked to abdominal obesity, which can be found even among individuals who are not considered obese by body weight standards. Imaging techniques such as computed tomography and magnetic resonance imaging have revealed the link between regional body fat partitioning and cardiometabolic risk. Visceral obesity is the most dangerous form of obesity, with subcutaneous obesity being associated with lower health risk. We have proposed that excess visceral fat may be a marker of subcutaneous adipose tissue dysfunction not being able to serve as a metabolic sink, causing lipid accumulation at undesired sites, a condition described as ectopic fat deposition. Among the effective approaches to prevent, delay, or manage metabolic syndrome, lifestyle changes are the key elements, with an emphasis on the importance of healthy global dietary patterns, regular physical activity, and adequate sleep quality. 517 $aMetabolic Syndrome 606 $aHumanities$2bicssc 606 $aSocial interaction$2bicssc 610 $aabdominal obesity 610 $aacylcarnitines 610 $aadolescent 610 $aadolescents 610 $aanthropometric indexes 610 $aanthropometric indices 610 $aatherosclerotic cardiovascular disease 610 $abirth weight 610 $ablood pressure 610 $abone health 610 $abone mineral density 610 $abranched-chain amino acids 610 $abreastfeeding duration 610 $acaloric restriction 610 $acarbohydrate 610 $acardiometabolic 610 $acardiometabolic risk 610 $acardiorespiratory fitness 610 $acardiovascular disease 610 $achronotype 610 $acity planning 610 $adiagnosis criteria 610 $adiet 610 $adiet quality 610 $adietary guidelines 610 $adietary intake 610 $adietary protein sources 610 $aelderly 610 $aendocannabinoidome 610 $aendocannabinoids 610 $aenergy balance 610 $aethnicity 610 $aexercise 610 $aexercise training 610 $afat intake 610 $afatty liver index (FLI) 610 $afish oil 610 $afructose 610 $agas-chromatography mass spectrometry 610 $aglucose 610 $ahealth check-up 610 $ahealth guidance 610 $ahealthy lifestyle score 610 $ahigh-carbohydrate 610 $ahigh-fat diet 610 $ahypertriglyceridemia 610 $ainsulin resistance 610 $alifestyle 610 $alinseed 610 $alipids 610 $amacronutrient intake 610 $ameat 610 $ameta-analyses 610 $ametabolic syndrome 610 $ametabolic syndrome (MetS) 610 $ametabolism 610 $ametabolite profiling 610 $ametabolomics 610 $amicrobiome 610 $amonounsaturated fat 610 $an/a 610 $anon-alcoholic fatty liver disease 610 $anonalcoholic fatty liver disease 610 $aobesity 610 $aolder adults 610 $aosteoporosis 610 $apediatric 610 $apediatric obesity 610 $aphysical activity 610 $apolyunsaturated fat 610 $aprevention 610 $arisk 610 $asaliva 610 $asaturated fat 610 $asaturated fatty acids 610 $asecoisolariciresinol diglucoside 610 $asleep 610 $asleep apnea 610 $asleep duration 610 $asleep habit 610 $asocial jetlag 610 $asugar-sweetened beverages 610 $aSUN cohort 610 $atrimethylamine N-oxide (TMAO) 610 $atype 2 diabetes 610 $auniversal public health screening program 610 $avisceral adiposity index (VAI) 610 $avisceral fat accumulation 610 $aweight gain 615 7$aHumanities 615 7$aSocial interaction 700 $aLemieux$b Isabelle$4edt$01302075 702 $aDespre?s$b Jean-Pierre$4edt 702 $aLemieux$b Isabelle$4oth 702 $aDespre?s$b Jean-Pierre$4oth 906 $aBOOK 912 $a9910557432803321 996 $aMetabolic Syndrome$93026101 997 $aUNINA